Calico Life Sciences is a biotechnology company focused on understanding and addressing the biology of aging. Founded in 2013 by Google, Calico's mission is to develop innovative therapies that can potentially increase human lifespan and improve healthspan, the period of life spent in good health. The company's approach involves a deep understanding of the complex biological processes that contribute to aging, with the goal of identifying potential therapeutic targets to prevent or treat age-related diseases.
Research and Development
Calico’s research and development efforts are centered around understanding the underlying mechanisms of aging. The company’s scientists employ a range of experimental and computational approaches, including genomics, epigenomics, and proteomics, to study the biology of aging in various model organisms, including mice, worms, and cells. By analyzing large datasets and identifying patterns and correlations, Calico’s researchers aim to uncover new insights into the aging process and identify potential targets for intervention.
Key Areas of Focus
Calico’s research is focused on several key areas, including cellular senescence, mitochondrial function, and stem cell biology. The company’s scientists are working to understand how these processes contribute to aging and age-related diseases, such as cancer, cardiovascular disease, and neurodegenerative disorders. By elucidating the underlying mechanisms, Calico hopes to develop novel therapies that can promote healthy aging and prevent or treat these diseases.
| Research Area | Description |
|---|---|
| Cellular Senescence | Study of how cells become senescent and contribute to aging and age-related diseases |
| Mitochondrial Function | Investigation of the role of mitochondria in aging and age-related diseases |
| Stem Cell Biology | Research on the biology of stem cells and their potential for regenerative medicine |
Collaborations and Partnerships
Calico collaborates with leading research institutions, universities, and companies to advance its mission. The company has established partnerships with organizations such as the Broad Institute, Stanford University, and AbbVie to leverage their expertise and resources. These collaborations enable Calico to access new technologies, share knowledge, and accelerate the development of novel therapies.
Notable Partnerships
Calico has formed several notable partnerships, including a collaboration with QB3 (California Institute for Quantitative Biosciences) to develop new therapies for age-related diseases. The company has also partnered with AncestryDNA to study the genetics of aging and longevity. These partnerships demonstrate Calico’s commitment to collaboration and its dedication to advancing the field of aging research.
- Broad Institute: Collaboration on genomics and epigenomics research
- Stanford University: Partnership on stem cell biology and regenerative medicine
- AbbVie: Collaboration on development of novel therapies for age-related diseases
What is Calico's approach to understanding the biology of aging?
+Calico's approach involves a deep understanding of the complex biological processes that contribute to aging, using a range of experimental and computational approaches, including genomics, epigenomics, and proteomics.
What are some of the key areas of focus for Calico's research?
+Calico's research is focused on several key areas, including cellular senescence, mitochondrial function, and stem cell biology, with the goal of understanding how these processes contribute to aging and age-related diseases.
Calico Life Sciences is at the forefront of aging research, leveraging cutting-edge technologies and collaborations to advance our understanding of the biology of aging. The company’s innovative approach and commitment to developing novel therapies have the potential to transform the field of aging research and improve human healthspan.
